Association of race and ethnicity with opioid prescribing for Medicare beneficiaries following total joint replacements

Abstract

AbstractBackgroundProfound racial and ethnic disparities exist in the use and outcomes of total hip/knee replacements (total joint replacements [TJR]). Whether similar disparities extend to post‐TJR pain management remains unknown. Our objective is to examine the association of race and ethnicity with opioid fills following elective TJRs for White, Black, and Hispanic Medicare beneficiaries.MethodsWe used the 2019 national Medicare data to identify beneficiaries who underwent total hip/knee replacements. Primary outcomes were at least one opioid fill in the period from discharge to 30 days post‐discharge, and 31–90 days following discharge. Secondary outcomes were morphine milligram equivalent per day and number of opioid fills. Key independent variable was patient race‐ethnicity (non‐Hispanic White, non‐Hispanic Black, Hispanic). We estimated multivariable hierarchical logistic regressions and two‐part models with state‐level clustering.ResultsAmong 67,550 patients, 93.36% were White, 3.69% were Black, and 2.95% were Hispanic. Compared to White patients, more Black patients and fewer Hispanic patients filled an opioid script (84.10% [Black] and 80.11% [Hispanic] vs. 80.33% [White], p < 0.001) in the 30‐day period. On multivariable analysis, Black patients had 18% higher odds of filling an opioid script in the 30‐day period (odds ratio [OR]: 1.18, 95% confidence interval [CI]: 1.05–1.33, p = 0.004), and 39% higher odds in the 31–90‐day period (OR: 1.39, 95% CI: 1.26–1.54, p < 0.001). There were no significant differences in the endpoints between Hispanic and White patients in the 30‐day period. However, Hispanic patients had 20% higher odds of filling an opioid script in the 31‐ to 90‐day period (OR: 1.20, 95% CI: 1.07–1.34, p = 0.002).ConclusionsImportant race‐ and ethnicity‐based differences exist in post‐TJR pain management with opioids. The mechanisms leading to the higher use of opioids by racial/ethnic minority patients need to be carefully examined.